Form 4: LeMaitre Vascular Director Acquires Shares Upon PSU Settlement and Dividend Equivalent Release

Director John James O'Connor acquired 204 shares of LeMaitre Vascular (LMAT) common stock upon settlement of a Performance Share Unit (PSU) award and 1 share upon release of dividend equivalent rights on February 28, 2025.

Summary

• On February 28, 2025, John James O'Connor, a director of LeMaitre Vascular Inc. (LMAT), acquired 204 shares of common stock upon the settlement of a Performance Share Unit (PSU) award.
• The PSU award was granted on December 8, 2023, and vests over three years.
• O'Connor also acquired 1 share upon the release of dividend equivalent rights related to the PSU award.
• The price for the shares acquired upon settlement of the PSU was $0.
• Following these transactions, O'Connor directly owns 57,301 shares of LMAT common stock.
• A Limited Power of Attorney was executed on December 5, 2024, granting certain individuals the authority to execute SEC filings on O'Connor's behalf.

Sentiment

Score: 6

Explanation: The document is a standard SEC filing detailing insider transactions. It doesn't contain overtly positive or negative information, but the director's share acquisition could be interpreted as a mildly positive signal.

Positives

• The acquisition of shares by a director could be seen as a positive signal, indicating confidence in the company's future prospects.

Future Outlook

The PSU award vests in equal annual installments from the grant date (December 8, 2023) over the next two years, suggesting further potential share acquisitions by the director.

Industry Context

This is a standard SEC Form 4 filing, reflecting changes in beneficial ownership by a company insider. Such filings are common and provide transparency to the market regarding insider transactions.

Comparison to Industry Standards

• Insider transactions are a common occurrence in publicly traded companies.
• Monitoring these transactions can provide insights into management's perspective on the company's valuation and future prospects.
• Comparing the size and frequency of insider transactions at LeMaitre Vascular to those of its peers (e.g., Medtronic, Boston Scientific) could offer a broader understanding of insider sentiment within the medical device industry.

Stakeholder Impact

• The transaction may have a minor positive impact on shareholder sentiment due to the director's increased stake in the company.

Key Dates